Drug Trial Radar · NCT07938489
Effect of Single High-Dose Vitamin D3 Versus Placebo on Hospital Length of Stay in Children With Severe Pneumonia.
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
114
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Nov 15, 2026
Study completion Nov 15, 2026
Sponsor
- Lead sponsor
- Shaheed Mohtarma Benazir Bhutto Institue of TraumaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Severe pneumonia is a major cause of morbidity and mortality among children and often requires hospitalization and prolonged medical care. Vitamin D plays an important role in immune regulation and inflammatory responses, and its supplementation may help improve outcomes in respiratory infections. However, evidence regarding its effectiveness in reducing the duration of hospital stay among children with severe pneumonia remains limited. This randomized controlled trial will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children of either sex, aged 1-16 years, presenting with severe pneumonia will be enrolled through non-probability consecutive sampling. Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded. Eligible participants will be randomly allocated into two groups using sealed opaque envelopes. Group A will receive a single oral dose of 200,000 IU vitamin D3 dissolved in 10 mL of peanut oil, while Group B will receive 10 mL of peanut oil as placebo. Both preparations will be identical in color, taste, smell, consistency, and container. Participants will be followed until discharge. Hospital length of stay, defined as the period from admission to discharge, will be recorded for each patient. Data will be analyzed using SPSS version 20. Mean hospital length of stay will be compared between the two groups using an independent samples t-test, with p≤0.05 considered statistically significant. The study aims to determine whether a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia.
Conditions
- Severe Pneumonia in Children
Interventions
Vitamin D3 GroupDrug
Participants allocated to the vitamin D3 group will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.
Placebo (Peanut Oil Solution)Drug
Participants allocated to the placebo group will receive 10 mL of peanut oil solution orally. The placebo preparation will be identical to the vitamin D3 preparation in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Hospital Length of StayTime frame: From hospital admission until discharge (3-14 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Pediatircs, Mohtarma Benazir Bhutto Shaheed Hospital, Mirpur AJ&K
Lahore, Punjab Province, Pakistan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.